These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29633000)

  • 1. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F; Renzulli M; Negrini G; Brocchi S; Ferrarini A; Andreone A; Benevento F; Golfieri R; Morselli-Labate AM; Mastroroberto M; Badea RI; Piscaglia F
    Eur Radiol; 2018 Sep; 28(9):3611-3620. PubMed ID: 29633000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
    Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
    Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
    BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G; Furlan A; Agnello F; Cabibbo G; Marin D; Giannitrapani L; Genco C; Midiri M; Lagalla R; Brancatelli G
    Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Arizumi T; Ueshima K; Takeda H; Osaki Y; Takita M; Inoue T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    J Gastroenterol; 2014 Dec; 49(12):1578-87. PubMed ID: 24499826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
    Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N; Furlan A; Marsh JW
    Jpn J Clin Oncol; 2016 Sep; 46(9):839-44. PubMed ID: 27317737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.
    Jeon MY; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Kim HS; Kim SU; Park MS
    Liver Int; 2018 Sep; 38(9):1655-1663. PubMed ID: 29495116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
    World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I; Scionti A; Mismas V; Masi G; Vivaldi C; Bartolozzi C; Sacco R
    Oncology; 2014; 86(4):191-8. PubMed ID: 24800837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
    Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
    Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
    Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M; Macaluso FS; Valenza F; Virdone R
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
    Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
    Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
    Knieling F; Waldner MJ; Goertz RS; Zopf S; Wildner D; Neurath MF; Bernatik T; Strobel D
    Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
    Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.